Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Instil Bio, Inc. TIL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$7.00
-17.1%

Instil Bio, Inc. (TIL) is a Biotechnology company in the Healthcare sector, currently trading at $8.44. It has a SharesGrow Score of 35/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is TIL = $7 (-17.1% upside).

Valuation: TIL trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25).

Net income is $71M (loss), growing at +28.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $85M against $114M equity (Debt-to-Equity (D/E) ratio 0.75, moderate). Current ratio is 39.53 (strong liquidity). Debt-to-assets is 41.9%. Total assets: $204M.

Analyst outlook: 3 / 7 analysts rate TIL as buy (43%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 20/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 16/100 (Fail), Income ?/100 (Fail).

$7.00
▼ 17.06% Downside
Average Price Target
The 12-month price target for Instil Bio, Inc. is $7.00.

TIL SharesGrow Score Overview

43/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 20/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TIL

✗
VALUE Fail
20/100
TIL trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25). Analyst consensus target is $7, implying -17.1% from the current price $8. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
TIL: +0%/yr revenue is, +28.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet TIL: Debt-to-Equity (D/E) ratio 0.75 (moderate), Current ratio is 39.53 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
TIL: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 3 / 7 analysts rate TIL as buy (43%). Analyst consensus target is $7 (-17.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range5.67-42.79
Volume15.8K
Avg Volume (30D)48.48K
Market Cap$57.24M
Beta (1Y)2.03
Share Statistics
EPS (TTM)-10.70
Shares Outstanding$6.67M
IPO Date2021-03-19
Employees14
CEOBronson Crouch
Financial Highlights & Ratios
Gross Profit$-534K
EBITDA$-52.37M
Net Income$-71.37M
Operating Income$-52.91M
Total Cash$76.13M
Total Debt$85.18M
Net Debt$78.54M
Total Assets$203.52M
Price / Earnings (P/E)-0.8
Analyst Forecast
1Y Price Target$7.00
Target High$7.00
Target Low$7.00
Upside-17.1%
Rating ConsensusHold
Analysts Covering7
Buy 43% Hold 57% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS45783C2008

Price Chart

Track all markets on TradingView
TIL
Instil Bio, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
5.67 52WK RANGE 42.79

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
 NLTX
NLTX
Neoleukin Therapeutics, Inc.
$3.49
+1.45%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message